CeloNova BioSciences Announces Financing Arrangement with Congruent Investment Partners and SWK Holdings Corporation Proceeds to Support Company Growth, Ongoing Clinical Trial Enrollment and New Product Initiatives CeloNova BioSciences, Inc. (CeloNova), a medical device company that develops, manufactures and markets a family of innovative cardiovascular products based upon its novel Polyzene™-F […]
Financial
LivaNova (LIVN)’s Perceval Sutureless Aortic Heart Valve Awarded New Technology Add-On Payment From The Center For Medicare And Medicaid Services
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its Perceval® sutureless aortic heart valve received approval from the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment (NTAP). The Perceval valve met the CMS criteria for NTAP, including the demonstration […]
Cardiovascular Systems Reports Fiscal 2017 Fourth-Quarter Financial Results
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (NASDAQ: CSII): Conference Call Scheduled for Today, August 2, 2017, at 3:45 PM CT (4:45 PM ET) Revenues of $52.9 million grew 9% compared to fourth quarter last year Gross margin increased to 81.7% from 79.7% in the prior-year period Net income was $0.8 […]
Endologix Reports Second Quarter 2017 Financial Results
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2017. “While we are pleased with the overall results in the second quarter, the recovery in AFX®2 sales in the U.S. has been slower […]
Cardinal Health Completes Acquisition of Medtronic’s Patient Recovery Business
DUBLIN, Ohio, July 30, 2017 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has completed the acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion. The acquisition was funded with a combination of $4.5 billion in new senior unsecured notes, existing cash and borrowings under our existing credit […]
Allied Minds’ Portfolio Company Signature Medical Raises $2.5 Million in Series A Financing
BOSTON–(BUSINESS WIRE)–Signature Medical, Inc. (Signature Medical), an Allied Minds (LSE: ALM) portfolio company, today announced that it has completed a $2.5 million Series A funding round, including participation from Riot Ventures, an early stage investment group focused on emerging technologies; Bose Corporation, a global leader in audio innovation; and Allied […]
C. R. Bard, Inc. (BCR) Announces Second Quarter Results
MURRAY HILL, N.J.–(BUSINESS WIRE)–C. R. Bard, Inc. (NYSE:BCR) today reported 2017 second quarter financial results. Second quarter 2017 net sales were $979.7 million, an increase of 5 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, second quarter 2017 net sales increased 6 percent […]
AtriCure (ATRC) Reports Second Quarter 2017 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results. “We are executing on our strategy to deliver solid, balanced, results across our business while progressing forward our clinical trials and strategic initiatives,” […]
Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to […]
Edwards Lifesciences (EW) Reports Second Quarter Results
IRVINE, Calif., July 26, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2017. Second Quarter and Recent Highlights: Sales grew 11 percent to $842 million; underlying1 sales increased 15 percent […]



